Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
Author:
Affiliation:
1. Division of Medical Oncology, National Cancer Center Singapore, Singapore
2. Associate Professor, Division of Medical Oncology, National Cancer Center Singapore, 11 Hospital Drive, 169610, Singapore
3. Duke-NUS Medical School, Singapore
Abstract
Publisher
SAGE Publications
Subject
Oncology
Link
http://journals.sagepub.com/doi/pdf/10.1177/1758835919880429
Reference60 articles.
1. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
2. Comprehensive molecular portraits of human breast tumours
3. The clonal and mutational evolution spectrum of primary triple-negative breast cancers
4. Repeated observation of breast tumor subtypes in independent gene expression data sets
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer;npj Precision Oncology;2024-01-10
2. Predictors of Complete Pathological Response with Chemoimmunotherapy in Triple-Negative Breast Cancer: A Meta-Analysis;Onco;2023-12-28
3. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer;Biomedicine & Pharmacotherapy;2023-12
4. Anti-breast cancer activity of bioactive metabolites from Andrographis paniculata through inhibition of PI3K activity in triple negative breast cancer (MDA-MB-231) cells;Journal of Molecular Structure;2023-12
5. Recent advances in targeted strategies for triple-negative breast cancer;Journal of Hematology & Oncology;2023-08-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3